

University of California, San Francisco

CURRICULUM VITAE

Name: Thomas G Martin III, M.D.

Present Title: Associate Chief, Division of Hematology/Oncology
Director, Adult Blood and Marrow Transplantation Program
Professor of Clinical Medicine
UCSF School of Medicine

Address: Hematology/Oncology Clinic 4th Floor Box 0324
400 Parnassus Ave, UC Clinics, A453
University of California, San Francisco
San Francisco, CA 94143
Voice: 415-353-9365
Fax: 415-353-2467
Email: tom.martin@ucsf.edu

EDUCATION

1982 – 1985 Cornell University, Ithaca, NY; BA Genetics

1985 – 1989 University of Connecticut School of Medicine, Farmington, CT

1989 – 1990 Internship in Internal Medicine, Harbor-UCLA Medical Center, Torrance, CA

1990 – 1992 Residency in Internal Medicine, Harbor-UCLA Medical Center, Torrance, CA

1993 – 1996 Fellowship in Hematology/Oncology, UCSF Medical Center, San Francisco, CA.

LICENSES, CERTIFICATION

1991- present Medical Licensure, California (G70576)

1999 Medical Licensure, Texas

1997 – 2007 American Board of Medical Oncology, Board Certification

1992 – 2016 American Board of Internal Medicine, Board Certification

1996 – 2026 American Board of Hematology, Board Certification

PRINCIPAL POSITIONS HELD

1992 – 1993 Associate Physician, Fagan ER Medical Group, Burbank, CA.

1992 – 1993 Courtesy Staff, Department of Internal Medicine, Kaiser Permanente, Bellflower, CA.

- 1992 – 1993 Attending Physician, Emergency Department
Veterans Administration Medical Center, Long
Beach, CA.
- 1993 – 1996 Courtesy Staff, Department of Internal Medicine,
Kaiser Permanente, San Francisco, CA.
- 1993 – 1997 Staff Physician, Hematology/Oncology,
California Pacific Medical Center, San
Francisco, CA.
- 1993 – 1998 Assistant Adjunct Professor, Hematology and
Bone Marrow Transplant, Division of
Hematology/Oncology, University of California,
San Francisco, CA.
- 1999 – 2001 Assistant Professor of Medicine, Chief, Inpatient
BMT Unit, Director, BMT Fellowship Program,
Division of Blood and Marrow Transplantation,
Department of Medicine, MD Anderson Cancer
Center, Houston, TX
- 2001 – present Director, Matched Unrelated Donor Program,
Adult Leukemia and Bone Marrow
Transplantation, University of California, CA
- 2001 – 2003 Assistant Clinical Professor of Medicine, Adult
Leukemia and Bone Marrow Transplantation
Program, University of California, San
Francisco, CA
- 2003 – 2008 Associate Clinical Professor of Medicine, Adult
Leukemia and Bone Marrow Transplantation
Program, University of California, San
Francisco, CA
- 2004 – present Co-Director, Multiple Myeloma Translation
Initiative, University of California, San Francisco,
CA.
- 2019 - present Member, Committee on Human Research
(CHR), University of California, San Francisco,
CA.
- 2006 – 2012 Member, Committee on Human Research
(CHR), University of California, San Francisco,
CA.
- 2007 – 2015 Clinical Director, 11 Long Adult Stem Cell
Transplantation, University of California, San
Francisco, CA.

- 2009 – present Professor of Clinical Medicine, Adult Leukemia and Bone Marrow Transplantation Program, University of California, San Francisco, CA
- 2017 – present Co-Leader, Hematologic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
- 2018 – 2022 Interim Co-Chief, Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA
- 2018 – present Director, Hematology, Blood and Marrow Transplantation and Cellular Therapies Program, University of California, San Francisco, CA
- 2019 - present Clinical Director, 4th Floor Outpatient HBC Ambulatory Care Clinic
- 2022 – present Co-Leader Hematologic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
- 2022 - present Associate Chief, Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA

OTHER POSITIONS HELD CONCURRENTLY

- 2011 - present Research Director, Hematologic Malignancies Research Office
UCSF Medical Center, San Francisco, CA

HONORS AND AWARDS

- 1981 Valedictorian, Windsor High School, Windsor, CT.
- 1981 Dean's List Honors - Cornell University, University of Connecticut
- 1984 Cornell Tradition Fellow Award
- 1989 LANGE Book Award for Scholarship in Internal Medicine, University of Connecticut, Farmington, CT

- 2003 Faculty Teaching Award, Division of Hematology/Oncology, University of California, San Francisco, CA
- 2013 Center of the Year, Multiple Myeloma Research Consortium
- 2014 Nominated, Master Clinician, UCSF Medical Center

PROFESSIONAL ACTIVITIES

MEMBERSHIPS

- 1995 – present American Society of Hematology
- 1997- present American Society of Clinical Oncology
- 1997 – 2007 American Academy for the Advancement of Science
- 2000 - present American Society for Blood and Marrow Transplantation
- 2008 – 2012 Member, Committee on Human Research (CHR) Member, Clinical Research Office UCSF Cancer Center
- 2008 - 2016 Co-Chair, Hematology/Oncology P+T Subcommittee
- 2008 – 2013 Member, CIDP Credentialing Committee
- 2013 - present American Society of Clinical Oncology
- 2016 - present Society of Hematologic Oncology (SOHO)
- 2011 - present International Myeloma Society
- 2009 – present Multiple Myeloma Research Foundation
- 2018-present International Myeloma Working Group, International Myeloma Foundation

SERVICE TO PROFESSIONAL ORGANIZATIONS

- 2014 - 2017 American Society of Clinical Oncology, Myeloma Abstract Committee Plasma cell disorder committee
- 2014 – present National Comprehensive Cancer Network (NCCN) Panel Member, Multiple Myeloma
- 2016 – present Society of Hematologic Oncology (SOHO) Education Committee member

2022 – present	International Myeloma Foundation	Instructor, Chinese Physicians Class
2018 – present	International Myeloma Working Group	
2020 – present	Co-Chair, Immunotherapy Committee, International Myeloma Foundation	Panel member
2022	American Society of Hematology, Abstract Selection Committee	

SERVICE TO PROFESSIONAL PUBLICATIONS

2013 – present	Journal Reviewer, Editorial Board, AACR, ad hoc reviewer BLOOD and Clinical Leukemia, Lymphoma, Myeloma, Blood Advances
2022- present	Blood Cancers Today, Associate Editor

INVITED PRESENTATIONS - INTERNATIONAL

2014	Hematology Symposium April 2014: Advances in Myeloma, Tel Aviv, Israel	Lecturer
2015	International Myeloma Foundation, Rome, Italy: Topic - Antibody therapy in Relapsed and Refractory Myeloma	Lecturer
2016	3rd Annual Summit on Hematologic Malignancies, Whistler, Canada: Topic - Genetic Factors Associated with Response to Therapy for hematologic Malignancies	Lecturer

2017	International Myeloma Foundation, New Delhi, India: Topic - Toxicities from Immunotherapies in Multiple Myeloma	Lecturer
2018		Lecturer
2018	5 th Annual Summit on Hematologic Malignancies, Whistler, Canada: Topic – CD38 Monoclonal Antibody Therapy for Multiple Myeloma	Lecturer
2019	Asian Myeloma Society – International Myeloma Foundation Symposium, Beijing, China: Topic – Novel CAR T-cell Strategies for the Treatment of Multiple Myeloma	Lecturer
2019		Lecturer
2020	6 th Annual Summit on Hematologic Malignancies, Whistler, Canada: Topic – Role of Daratumumab in Frontline Multiple Myeloma	Lecturer
2021	Asian Myeloma Society – International Myeloma Foundation Symposium, Bangkok, Thailand: Topic – BCMA targeted antibodies and CAR T-cells for the Treatment of Multiple Myeloma	Lecturer
2022		Lecturer
2022	Asian Myeloma Network Summit – Virtual Summit: Topic: CAR T Cell Therapies for Multiple Myeloma	Lecturer
2023	Myeloma Education Program, Melbourne, Australia: Topic – BCMA Targeted Therapeutics for Myeloma	
	Myeloma Canada: 12 th Annual Scientific Roundtable: Topic – Next Generation Therapeutics for Multiple Myeloma	
	Asian Myeloma Network Virtual Meeting: Update Immunotherapy in the United States	
	IMWG – Working Committee Meeting: Frankfurt Germany CAR T-cells Update	

INVITED PRESENTATIONS - NATIONAL AND INTERNATIONAL

1996	Presidential Plenary Session: Annual Meetings of the AGA and AASLD, San Francisco, CA, May 1996. Topic: Thrombopoietin May Play a Major Role in the Thrombocytopenia in Cirrhosis.	Lecturer
------	---	----------

1996	Grand Rounds: Department of Laboratory Medicine, UCSF Medical Center, August 1996. Topic: Thrombocytopenia in Health and Disease.; Intramural Meetings	Lecturer
1996	Grand Rounds: Department of Medicine, Division of Gastroenterology, UCSF Medical Center, December 1996. Topic: Thrombocytopenia in Cirrhosis.; Intramural Meetings	Lecturer
1998	Hemostasis and Thrombosis Seminar: Department of Medicine, Division of Hematology and Oncology, UCSF Medical Center, March 1998. Topic: New Thrombopoietic Agents-Preclinical and Clinical Studies.; Intramural Meetings	Lecturer
2000	International Symposium: XXIV Hematology Congress of Brasil; Rio de Janeiro, Brasil May 2000. Topic: Prevention and Management of Chemotherapy-Induced Thrombocytopenia, Invited Lectures	Lecturer
2000	American Society of Hematology: Symposium; San Francisco, CA December 2000. New Horizons for Acute Myelogenous Leukemia Patients with Limited Treatment Options: Topic: Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia, Invited Lectures	Lecturer
2001	German Leukemia Society: International Symposium; Munich, Germany, February 2001. Topic: Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous leukemia, Invited Lectures	Lecturer
2001	Whistler Oncology Seminar: New Developments in Oncology; Whistler, Canada, February 2001. Topic: New Treatments for Acute Myelogenous Leukemia, Invited Lectures	Lecturer
2001	American Society of Blood and Marrow Transplantation: Pharmacy Symposium, Keystone, CO, March 2001. Topic: Non-Myeloablative Transplantation for the Treatment of Hematopoietic Malignancies, Invited Lectures	Lecturer
2001	City of Hope Seminar: Rational Therapeutics: A Seminar in General Medicine; Anaheim, CA, June 2001. Topic: Utilization of Monoclonal Antibodies in Oncology, Invited Lectures	Lecturer

2000	International Oncology Network: Seminar: ASH Updates: Scottsdale, AZ, April 2002. Topic: New Treatments for Acute Myelogenous Leukemia, Invited Lectures	Lecturer
2002	Grand Rounds: Veterans Administration Hospital, Westwood, CA 2002. Topic: Targeted therapy for Relapse Acute Myelogenous Leukemia , Invited Lectures	Lecturer
2001	Silverado Oncology Conference, Napa CA 2003. Topic: New Therapies for Treating Fungal Infections in the Immunocompromised Host, Invited Lectures	Lecturer
2000	California Blood Bank Society, Berkeley, CA 2004. Topic: Advances in Stem Cell Transplantation, Invited Lectures	Lecturer
2000	Association of Northern California Oncologists, Berkeley, CA 2005. Topic: ASH Updates in Myeloma and Myelodysplasia, Invited Lectures	Lecturer
2001	Leukemia and Lymphoma Society Patient Advocacy Group, CA 2005. Topic: Advances in Myeloma, Invited Lectures	Lecturer
2002	ASH Review: Advances in Myeloma Treatment; San Francisco, CA 2007., Invited Lectures	Lecturer
2003	ASH Update: Advances in Supportive Care for Stem Cell Transplantation; San Francisco, CA, Invited Lectures	Lecturer
2008	Leukemia and Lymphoma Society; Patient Advocacy Group, Oakland, CA Advances in Myeloma, Invited Lectures	Lecturer
2008	Grand Rounds: San Francisco, VA Medical Center: Advances in Myeloma, Invited Lectures	Lecturer
2009	UCSF Clinical Cancer Update at Squaw Valley, CA: Advances in Myeloma, Invited Lectures	Lecturer
2010	UCSF Helen Diller Comprehensive Cancer Center Symposium: Clinical Developments in Multiple Myeloma	Lecturer
2011	Treatment of Relapse Myeloma: CME Lecture. Seattle, Washington.	Lecturer
2012	Multiple Myeloma Research Consortium: Patient Seminars; multiple events - San Francisco, CA; Scottsdale, AZ; Westwood, CA.	Lecturer

2014	Meet the Professor; April 2014: Novel Therapies in RRMM, Hadassah University, Jerusalem, Israel	Lecturer
2013	American Society of Hematology, Oral Presentation: Phase I Dose Escalation Trial of Single Agent SAR650984 in Relapsed Myeloma, San Francisco, CA	Lecturer
2014	American Society of Clinical Oncology, Oral Presentation: Phase I Dose Escalation Trail of SAR650984 in Combination with Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma, Chicago, IL	Lecturer
2014	American Society of Hematology 56th Annual Meeting, Oral Presentation: Personalizing Multiple Myeloma Treatment for Maximum Benefit, San Diego, CA	Lecturer
2015	Association of Northern California Oncologists (ANCO): Hematologic Malignancies Update: Update in Myeloma, Sacramento, CA	Lecturer
2015	International Myeloma Working Group Meetings (IMWG): Presentation: Novel Monoclonal Antibodies in Multiple Myeloma. Rome, Italy	Lecturer
2015	American Society of Hematology 57th Annual Meeting, Oral Presentation: Immunotherapy for the Treatment of Multiple Myeloma, Atlanta, GA	Lecturer
2016	Annual Oncology Symposium: Swedish Medical Center, Seattle Washington. Oral Presentation: Frontline Therapy for Multiple Myeloma	Lecturer
2016	Society of Hematologic Oncology (SOHO): Houston, TX. Current Frontline Therapy for Multiple Myeloma	Lecturer
2017	American Society of Clinical Oncology, Oral Presentation: Primary Refractory Myeloma, Chicago, IL	Lecturer
2017	Society of Hematologic Oncology: Houston, TX. Immunotherapy in Myeloma - Clues to Use of Monoclonal Antibodies	Lecturer
2017	International Myeloma Working Group Meetings: Presentation: Novel Immunotherapies in Myeloma – An update on Isatuximab, New Delhi, India	Lecturer

2018	4th Annual Symposium for Immuno-Oncology in Multiple Myeloma, San Francisco, CA – Novel Antibody Therapy	Lecturer
2019	Great Debates: Hematologic Malignancies Updates – Topics: Immunotherapy in multiple myeloma and Minimal residual disease testing. Marina Del Rey, CA and NY, NY.	Lecturer
2019	International Myeloma Working Group Meetings: Presentation: CD38 Next Generation therapies, Boston MA	Lecturer
2020	COMy Myeloma Meetings: Presentation: The future of CD38 Antibodies, Virtual Meeting Paris, France	Lecturer
2020	American Society of Clinical Oncology: Discussant – Harnessing Immunotherapy: Topic – Bispecific Antibodies: a “2 for 1”	Lecturer

2022	International Myeloma Working Group Meetings: MRD assessments in Multiple Myeloma, Los Angeles, CA	Lecturer
2022	Society of Hematologic Oncology: Houston, TX. Debate: CARs vs Bispecifics in Multiple Myeloma – Pro-Bispecific	Lecturer
2022	Shanghai's International Myeloma & Lymphoma Summit: Keynote: Updates in Immunotherapy in the United States	Lecturer

OTHER PROFESSIONAL SERVICE

2021-present	German Myeloma Group: GMMG-HD7 Study Data Safety Monitoring Committee	Chair
2021-present	LOXO - 20020 and 20023 Studies: Pirtobrutinib in CLL Data Safety Monitoring Committee	Member

UNIVERSITY AND PUBLIC SERVICE

UCSF CAMPUSWIDE

2008 – 2012	CIDP Credentialing Committee	Member
2018 - present	UCSF Health, Capital Budget Committee	Member
2018 – present	UCSF Cancer Center – Governance Committee	Member
2018 - present	Homegrown CAR T-cells Initiative	Member, Steering Committee

SCHOOL OF MEDICINE

2019 – present	Committee on Human Research	Member
2008 – 2012	Committee on Human Research	Member

SCHOOL OF PHARMACY

2010 - 2017	P+T Oncology Sub-Committee	Member
-------------	----------------------------	--------

DEPARTMENTAL SERVICE

2010 - present	Hematologic Malignancies Research Program	Director
2004 - 2019	Matched Unrelated Donor Selection Committee	Director

2017 – 2021	Helen Diller Family Comprehensive Cancer Center, Hematologic Malignancies Program	Co-Lead
2021 - present	Helen Diller Family Comprehensive Cancer Center, Cancer Immunology and Immunotherapy Program	Co-Lead

TEACHING/MENTORING EXPERIENCE

2000-2001	Director, Fellowship Program, MD Anderson, Blood and Marrow Transplantation Program
2001-2014	Core-Leader, UCSF Hematology/Oncology Fellowship Program, 11-Long Didactic Series
2001-present	Instructor, UCSF Medical School, Hematology Core Curriculum

PEER REVIEWED PUBLICATIONS

1. Malchoff CD, Javier EC, Malchoff DM, **Martin TG**, et al: Primary Cortisol Resistance Presenting as Isosexual Precocity. *Journal of Endocrinology and Metabolism*. 70:2, 503-9, 1990. PMID: 2105334
2. Meng YG, **Martin TG**, Peterson ML, Shuman MA, Cohen RL, Wong WL. Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. *Br J Haematol*. 1996 Dec; 95(3):535-41. PMID: 8943898
3. **Martin TG**, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, Shuman MA. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. *Ann Intern Med*. 1997 Aug 15; 127(4):285-8. PMID: 9265428
4. **Martin TG**, Shuman MA. Interferon-induced thrombocytopenia: is it time for thrombopoietin. *Hepatology*. 1998 Nov; 28(5):1430-2. PMID: 9794932
5. Anderlini P, Donato M, Lauppe MJ, Huh YO, **Martin TG**, Chan KW, Champlin RE, Körbling M. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. *Br J Haematol*. 2000 Jun; 109(4):770-2. PMID: 10929027
6. Shimoni A, Gajewski JA, Donato M, **Martin T**, O'Brien S, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. *Biol Blood Marrow Transplant*. 2001; 7(10):568-75. PMID: 11760089
7. **Martin TG**, Linker CA. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. *Hematol Oncol Clin North Am*. 2001 Feb; 15(1):121-43. PMID: 11253604
8. **Martin TG**, Gajewski JL. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. *Hematol Oncol Clin North Am*. 2001 Feb; 15(1):97-120. PMID: 11253611
9. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Körbling M, **Martin TG**, Ueno NT, Champlin RE, Khouri IF. Risk of therapy-related

myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. *Ann Oncol*. 2002 Mar; 13(3):450-9. PMID: 11996478

10. Thall PF, Inoue LY, **Martin TG**. Adaptive decision making in a lymphocyte infusion trial. *Biometrics*. 2002 Sep; 58(3):560-8. PMID: 12229990
11. **Martin TG**, Giralto S, Khouri I, Champlin RE: Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia. *Acute Leukemias IX. Hematology and Blood Transfusion*. 41:483-484, 2003.
12. Wong R, Giralto SA, **Martin TG**, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. *Blood*. 2003 Oct 15; 102(8):3052-9. PMID: 12842990
13. Gunn N, Damon L, Varosy P, Navarro W, **Martin TG**, Ries C, Linker C. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. *Biol Blood Marrow Transplant*. 2003 Oct; 9(10):643-8. PMID: 14569560
14. Khorshid O, de Meis E, **Martin TG**, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralto S, Champlin R, de Lima M. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. *Leukemia*. 2003 Dec; 17(12):2538-40. PMID: 14523458
15. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, **Martin TG**, Giralto S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. *Blood*. 2004 Aug 1; 104(3):649-54. PMID: 15069017
16. Damon L, Rugo H, Tolaney S, Navarro W, **Martin TG**, Ries C, Case D, Ault K, Linker C. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. *Biol Blood Marrow Transplant*. 2006 Mar; 12(3):316-24. PMID: 16503501
17. Lekakis L, Giralto S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, **Martin TG**, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. *Bone Marrow Transplant*. 2006 Sep; 38(6):421-6. PMID: 16892072
18. de Lima M, Champlin RE, Thall PF, Wang X, **Martin TG**, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralto S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. *Leukemia*. 2008 Feb; 22(2):258-64. PMID: 17989720
19. Damon L, Damon LE, Gaensler K, Kaplan L, **Martin TG**, Rubenstein J, Linker C. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. *Bone Marrow Transplant*. 2008 Nov; 42(10):649-57. PMID: 18679366. PMCID: PMC4372391
20. **Martin TG**, Sharma M, Damon L, Kaplan L, Guglielmo BJ, Working M, O'Malley R and Linker C. Voriconazole is Safe and Effective as Prophylaxis for Early and Late Fungal

Infections Following Allogeneic Hematopoietic Stem Cell Transplantation. *Transpl Infect Dis.* 2010 Feb; 12(1):45-50. 19793068

21. **Martin TG** and Wolf J. Bortezomib: Safety and Efficacy in the Treatment of Multiple Myeloma. *Clinical Medicine Reviews in Oncology.* 2010 Nov; 10:4137.
22. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, **Martin TG**, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC. Perifosine Plus Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase I/II Trial: *J Clin Oncol.* 2011 Nov 10; 29(32):4243-9. PMID: 21990396
23. Linker C, Damon L, **Martin TG**, Blume K, Forman S, Snyder D, Wolf J, Negrin R. Autologous hematopoietic cell transplantation for high-risk ALL. *Bone Marrow Transplant.* 2011 Mar; 46(3):460-1. PMID: 20531287
24. McCarthy P, Hofmeister C, Hurd D, Hassoun H, Richardson P, Giralt S, Stadmauer E, Weisdorf D, Vij R, Moreb J, Callander N, van Besein K, Gentile T, Isola L, Maziarz R, Gabriel T, Bashey A, Landau H, **Martin TG**, Qazilbash M, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelley M, Seiler M, Rosenbaum C, Hari P, Pasquini M, Horowitz M, Shea T, Devine S, Anderson K, Linker C. A phase III randomized, double-blind study of maintenance therapy with lenalidomide or placebo following autologous hematopoietic cell transplantation for multiple myeloma: for the Cancer and Leukemia Group B / Eastern Cooperative Oncology Group / Blood and Marrow Transplant Clinical Trials Network. *N Engl J Med.* 2012 May 10;366(19):1770
25. Siegel DS, **Martin TG**, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood.* 2012 Oct 4; 120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25. PMID: 22833546
26. Wang M, **Martin TG**, Bensinger W, Alsina M, Siegel D, Kavalierchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. *Blood.* 2013 Oct 31; 122(18):3122-8. PMID: 24014245 PMCID: PMC3814729
27. Niesvizky R, **Martin TG**, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. *Clin Cancer Res.* 2013 Apr 15; 19(8):2248-56. PMID: 23447001. PMCID: PMC4149337
28. Siegel D, **Martin TG**, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in four phase II clinical studies. *Hematologica.* 2013 Nov; 98 (11): 1753-61. PMID: 23935022 PMCID: PMC3815177

29. **Martin TG**. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. *Oncology (Williston Park)*. 2013 Dec; 27 Suppl 3:4-10. PMID: 25184230
30. Badros AZ, Vij R, **Martin TG**, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. *Leukemia*. 2013 Jan 31. doi: 10.1038/leu.2013.29. PMID: 23364621 PMCID: PMC3740399
31. Jakubowiak AJ, Siegel DS, **Martin TG**, Wang M, Vij, R, Lonial S, Trudel, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison B, Wong A, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agents carfilizomib in the PX-171-003-A1 study. *Leukemia*. 2013 Dec; 27(12): 2351-6. PMI D: 23670297 PMCID: PMC3865533
32. Niesvizky R, **Martin TG**, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase 1b dose-escalation study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. *Clin Cancer Res*. 2013 Apr 15;19(8):2248-56. doi: 10.1158/1078-0432.CCR-12-3352. Epub 2013 Feb 27. PMID: 23447001 PMCID: PMC4149337
33. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, **Martin TG**. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. *Bone Marrow Transplant* 2014; 10.1038. PMID: 25243620
34. Keller JW, Andreadis C, Damon LE, Kaplan LD, **Martin TG**, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. *J Geriatr Oncol*. 2014 Jul; 5(3):238-44. PMID: 24894413
35. Vij R, Mazumder A, Klinger M, O'Dea D, Paasch J, **Martin TG**, Weng L, Park J, Fiala M, Faham M, Wolf J. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. *Clin Lymphoma Myeloma Leuk*. 2014 Apr 14(2): 131-139. PMID: 24629890
36. Marra J, Greene J, Hwang J, Du J, Damon L, **Martin TG**, Venstrom JM. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia. *J Immunol* 2015. May 1;194(9):4222-30. PMID: 25810393
37. Mannis G, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai W, Gaensler K, Kaplan L, Koplwicz Y, Linker C, Olin R, Sayre P, Smith C, Sudhindra A, Venstrom JM, Wolf J, **Martin TG**. A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia, *Clin Lymphoma Myeloma Leuk*. 2015 Jun;15(6):377-83. PMID: 25776193
38. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, **Martin TG**.

Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. *Bone Marrow Transplant.* 2015 Jan; 50(1):40-4. PMID: 25243620

39. Sherbenou DW, Behrens CR, Su Y, Wolf JL, **Martin TG**, Liu B. The development of potential antibody-based therapies for myeloma. *Blood Rev.* 2015 Mar; 29(2):81-91. PMID: 25294123
40. Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczynszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, **Martin TG**, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patient. *Nat Commun.* 2015 Jul 22;6:7539. PMID: 26648255 PMCID: PMC5729160
41. Baz RC, **Martin TG**, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. *Blood* 2016 May 26;127(21):2561-8. PMID: 26932802
42. Mannis GN, **Martin TG**, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis A. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. *Leuk Lymphoma* 2016 Jul; 57(7):1560. PMID: 26490487
43. Mannis GN, **Martin TG**, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KM, Sayre PH, Wolf JL, Logan AC. Quantification of acute lymphoblastic leukemia clonotypes in leukapheresed peripheral blood progenitor cells predicts relapse risk after autologous hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2016 Jun;22(6):1030. PMID: 26899561
44. Mule MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, **Martin TG**, Hourigan CS. Multigene measurable residual disease assessment improves acute myeloid leukemia relapse risk stratification in autologous hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 2016 Nov;22(11):1974. PMID: 27544285 PMCID: PMC5072749
45. Sherbenou DW, Aftab BT, Su y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, **Martin TG**, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. *J Clin Invest* 2016 Dec 1;126(12):4640. PMID: 27841764 PMCID: PMC5127683
46. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, **Martin TG**, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple myeloma: version 3.2017. NCCN clinical practice guidelines in oncology. *J Natl Compr Cenc Netw.* 2017 Feb;15(2):230. PMID: 28188192

47. A Vogl DT, **Martin TG**, Vij R, Hari P, Mikheal JR, Seigel D, Wu KL, Delforge M, Gasparetto C. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. *Leuk Lymphoma* 2017 Aug;58(8):1872. PMID: 28140719
48. Le Moigne R, Aftab B, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, **Martin TG**, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M. The P97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of multiple myeloma. *Mol Cancer Ther* 2017 Sep;6 (Epub 2017) PMID: 28878026
49. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bahey A, Landau H, **Martin TG**, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after autologous stem-cell transplantation for multiple myeloma: a randomized, double-blind, phase 3 trial. *Lancet Haematol* 2017 Sep;4(9) (Epub 2017) Epub 2017 Aug 17. PMID: 28826616
50. **Martin TG**, Baz R, Benson D, Lendvai N, Wolf J, Munster P, Leshokhin AM, Wack C, Charpentier E, Campana F, Vij r. A Phase Ib study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. *Blood* 2017. Aug; 58(8):1872-1879. PMID: 30862646
51. Kumar SK, Callander NS, Alsina M, Atanackovic D, Bierman JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, **Martin TG**, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shea DA. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. *J Natl Compr Canc Netw*. 2018 Jan;16(1):11-20.
52. Tan M, Kalin-Hajdu E, Narayan R, Wong SW, **Martin TG**. Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma. *J Oncol Pharm Fract*. 2018 Jan 1:1078155218785967. Doi: 10.1177/1078155218785967. [Epub ahead of print] PubMed PMID: 30005587.
53. Leleu X, **Martin TG**, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk* 2019 Jan;19(1)9-22. Doi: 10.1016/j.clml.2018.08.016 Epub 2018 Sep 5. Review. PMID 30287200
54. Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, **Martin TG**, Heffner LT, Nooka AK, Harvey RD, Lonial S. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: Results of a Multiple Myeloma Research Consortium Phase I Study. *Blood Cancer J*. 2019 Jan 4:9(1):3. doi: 10.1038/s41408-018-0154-8. PubMed PMID: 30610196; PMCID: PMC6320362.
55. Nawas MT, Andreadis C, **Martin TG**, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY Olin RL. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 Jan 30.pii S1083-8791(19)30086-2. doi: 10.1016/j.bbmt.2019.01.028. [Epub ahead of print] PubMed PMID: 3070189.

56. **Martin TG**, Strickland S, Glenn M, Charpentier E, Guillermin H, Hsu K, Mikhael J. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. *Blood Cancer J*. 2019 Mar 29;9(4):41. doi: 10.1038/s41408-019-0198-4. PubMed PMID: 30926770; PubMed Central PMCID: PMC6440961.
57. Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, **Martin TG**. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. *J Clin Oncol*. 2019 Apr 1: JCO1802096. doi: 10.1200/JCO.18.02096. [Epub ahead of print] PubMed PMID:30932732.
58. Mikhael J, Ismaila N, **Martin TG**. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline Summary. *J Oncol Pract*. 2019 Apr 1:JOP1800782. Doi: 10.1200/JOP.18.00782. [Epub ahead of print] PubMed PMID: 30933544.
59. **Martin T** and Huff CA. Current Advances and Future Directions. *Clin Lymphoma Myeloma Leuk*. 2019 May;19(5):255-263. doi: 10.1016/j.clml.2019.03.025. Epub 2019 Apr 1.
60. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, **Martin T**, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R, NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. *J Natl Compr Canc Netw*. 2019 Oct 1;17(10):1154-1165.
61. **Martin TG**, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, Solanki M, Meng R, Lee H, Wiederschain D, Zhu C, Rak A, Anderson KC. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. *Cells*. 2019 Nov 26;8(12):1522. doi:10.3090/cells8121522
62. Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L, Kamperschroer C, Pascua E, Chen W, Delaria K, Farias S, Bateman M, Dushin RG, Chin SM, Van Blarcom TJ, Yeung YA, Lindquist KC, Chunyk AG, Kuang B, Han B, Mirsky M, Pardo I, Buetow B, **Martin TG**, Wolf JL, Shelton D, Rajpal A, Strop P, Chaparro-Riggers J, Sasu BJ. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma. *Mol Cancer Ther*. 2019 Nov;18(11):2008-2020.
63. Moreau P, Dimopoulos MA, Yong K, Mikhael J, Risse ML, Asset G, **Martin T**. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. *Future Oncol* 2020. Jan;16(2): 4347-4358;doi: 10.2217/fo-2019-0431. Epub 2019 Dec 13.
64. Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, **Martin TG 3rd**, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. Proteasome inhibitor-induced modulation reveals the sliceosome as a specific therapeutic vulnerability in multiple myeloma. *Nat Commun* 2020 Apr 22;11(1):1931.
65. Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, Bensinger W, Dimopoulos M, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Oprea C, Chiron M, Brillac C, Charpentier E, San-Miguel J, **Martin T**. A dose-finding phase II study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. *Leukemia*. 2020 May 14. doi: 10.1038/s41375-020-0857-2.

66. Kambhampati S, Galligan D, Huang CY, Wong S, Wolf J, **Martin T**, Shah N. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. *Luek Lymphoma* 2020 May;61(5):1211-1219. doi.10.1080/10428194.2019.1709835.
67. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, **Martin TG 3rd**. Impact of plerixafor use at different peripheral blood CD34(+) thresholds on autologous stem cell collection in patients with multiple myeloma. *Biol Blood Marrow Transplant* 2020 May;26(5):876-883.
68. Alonso R Cedena MT, Wong SW, Shah N, Rios-Tamayo R Moraleda JM, Lopez-jiminez J, Garcia C, Bahri N, Valeri A, Sanchez R, Collado-Yurrita L, **Martin T**, Wolf J, Lahuerta JJ, Martinez-Lopez J. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. *Blood Adv* 2020 May 26;4(10):2163-2171.
69. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, **Martin TG**, Wolf JL, Roybal KT, Pahl A, Tauton J, Wiita AP, Kampman M. CRISPR-based screens uncover determinants of immunomodulatory response in multiple myeloma. *Blood Adv* 2020 Jul 14;4(13)
70. Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y, Huang CY **Martin T**, Wolf J. Clinical value of measurable disease testing for assessing depth, duration and direction of response in multiple myeloma. *Blood Adv* 2020 Jul 28;4(14):3295-3301
71. Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, **Martin T**, Wolf J. Lahuerta JJ, Martinez-Lopez J. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. *PLoS One* 2020 Aug 31;15(8):e0237155. doi 10.1371/journal.pone.0237155
72. Narayan R, Galligan D, Lazar AA, Kim s, Fong R, Tan M, Lo M, Arora S, Shah N, Wong SW, **Martin T**, Wolf J. Modified HyperCVAD with proteasome inhibition for multiple myeloma: A single center retrospective analysis. *Clin Lymphoma Myeloma Leuk* 2020 Dec;20(12):e961-e985. Doi 10.1016/j.cclml.2020.07.015.
73. **Martin TG**, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. *Cancer* 2021 Mar 18. doi: 10.1002/cncr.33448.
74. Banerjee R, Marsal J, Huang CY, Lo M, Kambhampati S, Kenedy VE, Arora V, Wolf JL, **Martin TG**, Wong SW, Shah N. Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma. *Transplant Cell Ther* 2021 Mar 6:S2666-6367(21)00747-8
75. Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, **Martin T**, Yong K, Durie BGM, Facon T, Jurczynszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA,

Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.* *Lancet Oncol.* 2021 Mar;22(3):e105-e118.

76. Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, **Martin T**; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet.* 2021 Jun 19;397(10292):2361-2371.
77. Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Hung CY, **Martin T** 3rd, Damon L, Andreadis B. Ofatumumab, etoposide, and cytarabine intensive mobilization regimen in patients with high-risk relapsed/refractory diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. *Clin Lymphoma Myeloma Leuk* 2021 Apr;21(4):246-256.
78. Wong SW, Shah N, Ledergor G, **Martin T**, Wolf JL, Shui AM, Huang CY, Martinez-Lopez J. Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells. *Front Oncol.* 2021 Dec 6;11:783703.
79. Weisel K, **Martin T**, Krishnan A, Jagannath S, Londhe A, Nair S, Diels J, Vogel M, Schechter JM, Banerjee A, Berdeja JG, Nesheiwat T, Garrett A, Qi K, Valluri S, Usmani SZ, Yong K. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. *Clin Drug Investig* 2022 Jan;42(1):29-41
80. Raje NS, Anaissie E, Kumar SK, Lonial S, **Martin T**, Gertz MA, Krishnan A, Hari P, Ludwig H, O'Donnell E, Yee A, Kaufman JL, Cohen AD, Garderet L, Wechalekar AF, Terpos E, Khatri N, Niesvizky R, Yi Q, Joshua DE, Saikia T, Leung N, Engelhardt M, Mothy M, Branagan A, Chari A, Reiman AJ, Lipe B, Richter J, Rajkumar SV, Miguel JS, Anderson KC, Stadtmauer EA, Prabhala RH, McCarthy PL, Munshi NC. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. *Lancet Haematol* 2022 Feb;9(2):e143-e161.
81. Baljevic M, Sborov DW, Lim MY, Hillengass J, **Martin T**, Castillo JJ, Streiff MB, Kumar SK, Callander NS. Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma. *J Natl Compr Canc Netw.* 2022 Jan;20(1):91-95.
82. Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman B, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, **Martin T**, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. *J Natl Compr Canc Netw.* 2022 Jan;20(1):8-19.
83. Kim K, Min CK, Koh Y, Ishizawa K, Kim SH, Ito S, Tanaka J, Uchiyama M, Kawano Y, Kim JS, Moreau P, **Martin T**, Dong Y, Risse ML, Suzuki K. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. *Int J Hematol.* 2022 May 17.
84. **Martin TG**, Mikhael J, Hajek R, Kim K, Suzuki K, Hulin C, Garg M, Quach H, Sia H, George A, Konstantinova T, Risse ML, Asset G, Macé S, van de Velde H, Moreau P. Depth

- of response and response kinetics of Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. *Blood Adv.* 2022 May 20.
85. Dimopoulos MA, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, De la Rubia J, Maiolino A, Reiman T, Martinez-Lopez J, **Martin T**, Mikhael J, Yong K, Risse ML, Asset G, Marion S, Hajek R. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. *Am J Hematol.* 2022 May 23.
 86. Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, **Martin T**, Suvannasankha A, De Braganca KC, Corsale C, Schecter JM, Varsos H, Deraedt W, Wang L, Vogel M, Roccia T, Xu X, Mistry P, Zudaire E, Akram M, Nesheiwat T, Pacaud L, Avivi I, San-Miguel J. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. *Blood.* 2023 Jan 19;141(3):219-230.
 87. Costa LJ, Lin Y, Cornell RF, **Martin T**, Chhabra S, Usmani SZ, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schecter JM, Kumar S, Hari P. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk.* 2022 May;22(5):326-335.
 88. Capra M, Martin T, Moreau P, Baker R, Pour L, Min CK, Leleu X, Mohty M, Segura MR, Turgut M, LeBlanc R, Risse ML, Malinge L, Schwab S, Dimopoulos M. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. *Haematologica.* 2022 Jun 1;107(6):1397-1409.
 89. Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, **Martin TG 3rd**, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD Jr, Mullins RD, Eyquem J, Wells JA, Wiita AP. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. *Nat Commun.* 2022 Jul 15;13(1):4121.
 90. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, **Martin T**, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlir C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma. *N Engl J Med.* 2022 Aug 11;387(6):495-505.
 91. **Martin T**, Mikhael J, Hajek R, Kim K, Suzuki K, Hulin C, Garg M, Quach H, Sia H, George A, Konstantinova T, Risse ML, Asset G, Macé S, van de Velde H, Moreau P. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. *Blood Adv.* 2022 Aug 9;6(15):4506-4515.
 92. Weisel K, Krishnan A, Schecter JM, Vogel M, Jackson CC, Deraedt W, Yeh TM, Banerjee A, Yalniz F, Nesheiwat T, Van Sanden S, Diels J, Valluri S, Usmani SZ, Berdeja JG, Jagannath S, **Martin T**. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class

Exposed Relapsed or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):690-701.

93. **Martin T**, Richardson PG, Facon T, Moreau P, Perrot A, Spicka I, Bisht K, Inchauspé M, Casca F, Macé S, Van de Velde H, Suzuki K. Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA. Haematologica. 2022 Oct 1;107(10):2485-2491.
94. Leleu X, **Martin T**, Weisel K, Schjesvold F, Iida S, Malavasi F, Manier S, Chang-Ki Min, Ocio EM, Pawlyn C, Perrot A, Quach H, Richter J, Spicka I, Yong K, Richardson PG. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Ann Hematol. 2022 Oct;101(10):2123-2137.
95. Spicka I, Moreau P, **Martin TG**, Facon T, Martinez G, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Risse ML, Asset G, Macé S, van de Velde H, Yong K. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol. 2022 Nov;109(5):504-512.
96. Facon T, Moreau P, **Martin TG**, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Yong K, Risse ML, Asset G, Schwab S, Martinez G. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022 Dec;40(5):1020-1029.
97. **Martin T**, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, Hari P, Berdeja JG, Usmani SZ, Yeh TM, Olyslager Y, Goldberg JD, Schechter JM, Madduri D, Jackson CC, Deraedt W, Gries KS, Fastenau JM, Trudeau JJ, Akram M, Pacaud L, Jakubowiak A, Jagannath S. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol. 2022 Dec;9(12):e897-e905.
98. Slade M, **Martin TG**, Nathwani N, Fiala MA, Rettig MP, Gao F, Deol A, Buadi FK, Kaufman JL, Hofmeister CC, Gregory TK, Berdeja J, Chari A, Rosko A, Vij R. Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia. 2022 Dec;36(12):2917-2921
99. Dimopoulos MA, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, De la Rubia J, Maiolino A, Reiman T, Martinez-Lopez J, **Martin T**, Mikhael J, Yong K, Risse ML, Asset G, Marion S, Hajek R. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Am J Hematol. 2023 Jan;98(1):E15-E19.
100. Reyes KR, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Olin RL, **Martin T**, Shah N, Banerjee R. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. Transplant Cell Ther. 2023 Mar 17:S2666-6367(23)01171-5.
101. **Martin T**, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schechter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory

Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. *J Clin Oncol.* 2023 Feb 20;41(6): 1265-1274.

CONFERENCE ABSTRACTS

1. Molldrem JJ, Kant S, Lu S, Rios R, Streicher H, Wang C, Giralt S, O'Brien S, Cortes J, Champlin RC, **Martin TG**, Wieder E: Peptide Vaccination with PR1 Elicits Active T Cell Immunity That Induces Cytogenetic Remission in Acute Myelogenous Leukemia. *Blood*, 93: 8 8a, 2002.
2. Lowe J, Lee P, Fei D, Meng YG, Wong WL, Cohen RL, **Martin TG**, Morgan DA, Koren E: Bioassay for TPO Activity in Human Serum Using Megakaryoblastic HU-3 Cell Line. *Blood*, 86:10, 3601a, 1997.
3. **Martin TG**, and Shuman MA: Transfusion Therapy during Liver Transplantation is Dependent on the Pre-transplantation Platelet Count. *Blood*, 90:10, 3316a, 1997.
4. Lebeurier I, **Martin TG**, and Shuman, MA: Primitive Megakaryocyte Progenitors are Enriched in Cord Blood compared with Chemotherapy and G-CSF Mobilized Peripheral Blood. *Blood*, 86:10, 3376a, 1997.
5. de Lima M, Komanduri K, St. John L, Wieder E, Lee M, McMannis J, Karandish S, Giralt S, Beran M, Couriel D, Korbiling M, **Martin TG**, Andersson B, Bibawi S, Westmoreland M, Hosing C, and Champlin R. Using Two Mismatched Unrelated Donor Cord Blood Units For Transplantation: Analysis of Chimerism and Immune Reconstitution. *Blood*, 98:11, 5192a, 2001.
6. **Martin TG**, Shahjahan M, de Lima M, Couriel D, Champlin R, Gajewski J, Giles F, Kantarjian H, Andersson B and Giralt S. The Use of Mylotarg as Anti-leukemia Therapy Increases the Incidence of Liver Toxicity Including VOD Following Allogeneic Transplantation. *Blood*, 98:11, 803a, 2001
7. Anagnostopoulos A, de Lima M, Munsell M, Shahjahan M, Couriel D, **Martin TG**, Cano P, McMannis J, Gajewski J, Anderson B, Champlin R, Giralt S. Unrelated donor bone marrow transplantation (UDR) for adults with AML/MDS: similar outcomes with ablative or reduced intensity preparative regimens (RIPR). *Blood* 2002.
8. De Lima M, Wong R, **Martin TG**, Couriel D, Anagnostopoulos A, Shahjahan M, Hosing C, Andersson B, Donato M, Cano P, Ippoliti C, Estey E, Gajewski J, Champlin R, Giralt S. Unrelated Donor Hematopoietic Stem Cell Transplantation/> (HSCT) for the treatment of Myeloid Malignancies in Patients Older than 55 years of Age. *Blood* 2002.
9. Dhruva A, Damon L, Linker C, **Martin TG**, and Navarro W. A Retrospective Review of Outcomes of Patients with Chronic Myelomonocytic Leukemia Treated with 5-Azacitidine. *Blood*, Nov 2005; 106: 4931a.
10. Chari A, Kaplan L, Linker C, Damon L, Navarro W, and **Martin TG**. Phase I/II Study of Bortezomib in Combination with Liposomal Doxorubicin and Melphalan in Relapsed or Refractory Multiple Myeloma. *Blood*, Nov 2005; 106: 5182a.
11. Richardson P, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Allerton JP, Schlossman R, Ghobrial I, Munshi N, **Martin TG**, Laubach J, Colson K, Dean S, Tocco D, Steinfield E, Kendall T, O'Riley K, Hideshima T, Sportelli P, Gardner L, and Anderson K. Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

- Who Were Previously Relapsed from or Refractory to Bortezomib Blood, Nov 2008; 112: 870a.
12. **Martin TG**, Hong S, Damon L, Kaplan L, Navarro W, and Linker C. Tacrolimus, Mini-Methotrexate and Mycophenolate Mofetil is Safe and Effective as Acute GVHD Prophylaxis for Non-Myeloablative Unrelated Donor Allogeneic Transplantation. Blood Nov 2009
 13. Percival ME, Damon LE, **Martin TG**, Kaplan L, Ai W, Wolf JL, Hong S, Linker C, Ries C and Andreadis C. Long-Term Outcomes in Patients with Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation (AlloSCT) for Relapse After Initial Autologous Bone Marrow Transplant (ASCT). Blood Nov 2009.
 14. Giermasz A, MD, Damon E, Kaplan L, Navarro W, Hege, Linker C and **Martin TG**. Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy In Adults with Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation. Blood Nov 2010
 15. Siegel DS, Kaufman JL, Wang M, **Martin TG**, Jagannath S, Niesvizky R, Reu FJ, Alsina M, Badros A, Gabrail NY, Kukreti V, Singhal S, Le MH, Kotlovker D, Bomba D, Hannah AL, and Vij R. Carfilzomib in patients with relapsed and/or refractory multiple myeloma: summary of safety and efficacy data upon long-term treatment. International Myeloma Workshop 2011.Paris, France. May 3–6, 2011.
 16. Jakubowiak A, **Martin TG**, Singhal S, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Kunkel LA, Bray L, Vallone M, Wong AF, Orłowski RZ, Siegel DS, and The Multiple Myeloma Research Consortium (MMRC). Effects of cytogenetics on responses and survival in patients with relapsed and refractory multiple myeloma (R/R MM) treated with single-agent Carfilzomib. International Myeloma Workshop 2011.Paris, France. May 3–6, 2011.
 17. Niesvizky R, Bensinger W, **Martin TG**, Alsina M, Siegel D, Gabrail N, Hari P, Singhal S, Vescio R, Assouline S, Kunkel L, Vallone M, Wong A, Wang M. An UPDATE on the Phase 1b/2 Dose-escalation Study of Carfilzomib with Lenalidomide and Low-dose Dexamethasone (CRd) in PATIENTS WITH Relapsed or Refractory Multiple Myeloma. Blood, November 2011.
 18. **Martin TG**, Baz R, Benson D, Lendvai N, Campana F, Charpentier E, Vij R. A Phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Submitted ASH 2014
 19. Siegel DS, Berdeja JG, Infante J, Kaufman J, Wang M, **Martin TG**, Niesvizky R, Reu FJ, Jagannath S, Rajangam K, Huang M, Vij R. Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010). Submitted ASH 2014.
 20. Rachid Baz, MD, **Thomas G. Martin III, M.D.**, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Hearn J. Cho, MD, PhD, Jeffrey L Wolf, MD, Anuj Mahindra, M.D., Ajai Chari, MD, Daniel M Sullivan, MD, Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Xiuhua Zhao, Hui-Yi Lin, PhD and Sundar Jagannath, MD: Pomalidomide, Cyclophosphamide, and

Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study (56th ASH Annual Meeting Abstracts), Abstract 303, December 2014.

21. John Marra, BS, Juan Du, MD, PhD, Jimmy Hwang, Ph.D., Jeffrey L Wolf, MD, **Thomas G. Martin III, M.D.** and Jeffrey M Venstrom, MD: KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone (56th ASH Annual Meeting Abstracts), Abstract 2126, December 2014.
22. Blake T. Aftab, PhD, Daniel J Anderson, PhD, Ronan Le Moigne, PhD, Stevan Djakovic, PhD, Eugen Dhimolea, PhD, Megan Murnane, Emily King, Julie Rice, Steve Wong, Brajesh Kumar, PhD, Eduardo Valle, Mary-Kamala Menon, Szerenke Kiss von Soly, Jinhai Wang, PhD, Bing Yao, Ferdie Soriano, Martin Kampmann, PhD, Diego Alcost-Alvear, PhD, Marta Chesi, PhD, Leif Bergsagel, M.D., F. Michael Yakes, PhD, Han-Jie Zhou, PhD, David Wustrow, PhD, **Thomas G. Martin III, M.D.**, Jeffrey L. Wolf, M.D., Constantine S. Mitsiades, MD, PhD and Mark Rolfe, PhD: Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma (56th ASH Annual Meeting Abstracts), Abstract 4701, December 2014.
23. **Thomas G. Martin III, M.D.**, Rachid Baz, MD, Don M. Benson Jr., MD, PhD, Nikoletta Lendvai, MD, PhD, Frank Campana, MD, Eric Charpentier and Ravi Vij, MBBS, MD: A Phase 1b Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (56th ASH Annual Meeting), Abstract 83, December 2014.
24. Chari A, Richter JR, Shah N, Wong SWK, Jagannath S, Cho HJ, Biran N, Wolf J, Parekh SS, Munster P, Madduri D, Campana F, **Martin TG**. Phase Ib study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM). ASCO June 2018 Annual Meeting, Abstract 8014
25. **Martin TG**, Dimopoulos MA, Yong K, Mikhael J, Risse ML, Asset A, Moreau P. Phase III (IKEMA) study design: isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM). ASCO June 2018 Annual Meeting, Abstract 8060
26. **Martin T**, Shah N, Richter J, Vesole D, Wong S, Madduri D, Jagannath S, Biran N, Cho HJ, Wolf J, Parekh S, Munster P, Richard S, Campana F, and Chari A. Final Analysis of a Phase I-b Study of Isatuximab + Carfilzomib in Relapsed and Refractory Multiple Myeloma (RRMM) COMy April 2020 Annual Meeting, Abstract (Oral presentation).
27. **Martin T**, Usmani SZ, Berdeja JG, Jakubowiak A, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Myo Htut10, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schechter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Madduri D, Olyslager Y, Zhou C, Pacaud L, Lin Y, Jagannath S. Updated results for CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. ASH December 2021 (Oral presentation)

Signed

A handwritten signature in black ink, appearing to read 'T. Martin', with a long horizontal flourish extending to the right.

Thomas Martin, MD

12/02/2023